1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Towa’s First Quarter Performance Draws Analyst Optimism

The Japanese Firm Reported Significant Increases In Profit

 
• By Adam Zamecnik

Following Towa’s reveal of its medium-term business plan earlier this year, the company has shared its financial first quarter results, which were positively received by select analysts.

Japanese Yen
• Source: Shutterstock

Towa Pharmaceutical’s performance in the first quarter of the 2024 financial year has industry analysts optimistic on basis of increased profit.

The Japanese firm reported a 16.7% growth in gross profit from ¥20bn ($136.7m) in the first quarter of the 2024...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Advanz Claims Cimzia Biosimilar In Europe Following Alvotech-Xbrane Deal

 
• By Dean Rudge

A proposed biosimilar to one of the lesser spoken about monoclonal antibodies for inflammatory conditions, UCB Pharma’s Cimzia, is the latest candidate to join the significant commercial partnership between Alvotech and Advanz Pharma.

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By Dave Wallace

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.